首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Parkinson's disease in the limelight
【24h】

Parkinson's disease in the limelight

机译:帕金森氏病备受关注

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The 2014 Lasker-DeBakey Clinical Medical Research Award -one of three prestigious awards granted by the Lasker Foundation in recognition of scientists, clinicians and public servants who have made major advances in the understanding, diagnosis, treatment, cure or prevention of human disease- has been granted to two pioneers in the field of Parkinson's disease therapy. In spite of the availability of more than two dozen drugs and fixed-dose combination products to treat the symptoms of Parkinson's disease -most notably the gold standard levodopa, a dopamine precursor- As well as nonpharmacological treatments like deep brain stimulation, many patients do not respond to available drugs or experience breakthrough symptoms, and the disease is ultimately uncurable. This article reviews currently available therapies as well as biomarkers and novel diagnostics.
机译:2014年Lasker-DeBakey临床医学研究奖是Lasker基金会授予的三个著名奖项之一,以表彰在认识,诊断,治疗,治愈或预防人类疾病方面取得重大进展的科学家,临床医生和公务员。被授予帕金森氏病治疗领域的两位先驱。尽管有超过二十种药物和固定剂量组合产品可用于治疗帕金森氏病的症状-最著名的是金标准左旋多巴,多巴胺前体-以及诸如深部脑刺激的非药物疗法,但许多患者并未对可用药物产生反应或出现突破性症状,这种疾病最终无法治愈。本文介绍了当前可用的疗法以及生物标志物和新颖的诊断方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号